^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/22/2019
    Excerpt:
    XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for...Metastatic Colorectal Cancer...First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    04/20/2012
    Excerpt:
    Capecitabine Teva is indicated for the treatment of metastatic colorectal cancer.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Colorectal cancer...for patients with impaired tolerance to aggressive initial therapy, the guidelines recommend infusional 5-FU/LV or capecitabine with or without bevacizumab as an option.